Passage BIO, Inc. (PASG) shareholders
Close on Nov 17, 2026Market cap $13.58MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Weston Nichols Joint filing with Lynx1 Capital Management LP (21.00%) | 673,759 | 21.00% | 13D (active) | Jun 25, 2026 |
| Lynx1 Capital Management LP Joint filing with Weston Nichols (19.60%) | 623,704 | 19.60% | 13G (passive) amendment | Sep 30, 2025 |
| Orbimed Capital Gp Vii LLC Joint filing with Orbimed Advisors LLC (7.82%) | 243,878 | 7.82% | 13D (active) amendment | Jul 17, 2025 |
| David Paolella Joint filing with Baselake Partners, LP (7.30%), Baselake Management, LLC (7.30%) | 235,058 | 7.30% | 13G (passive) | Jun 18, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PASG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 2,886,125 | 89.69% | $4.31M | New | 0.00% |
| Lynx1 Capital Management LP | 673,759 | 20.94% | $3.29M | +50,055 | 0.38% |
| Vanguard Capital Management LLC | 113,964 | 3.54% | $556.14K | – | 0.00% |
| Balyasny Asset Management L.P. | 107,025 | 3.33% | $522.28K | New | 0.00% |
| Ikarian Capital, LLC | 99,517 | 3.09% | $485.64K | +31,393 | 0.05% |
| Yiheng Capital Management, L.P. | 86,097 | 2.68% | $420.15K | – | 0.14% |
| Renaissance Technologies LLC | 47,892 | 1.49% | $233.71K | −85,720 | 0.00% |
| Erste Asset Management GmbH | 40,665 | 1.26% | $197.23K | −44,597 | 0.00% |
| Geode Capital Management, LLC | 37,026 | 1.15% | $180.72K | −4,354 | 0.00% |
| Verdad Advisers, LP | 30,728 | 0.95% | $149.95K | +8,600 | 0.14% |
| Boothbay Fund Management, LLC | 28,439 | 0.88% | $138.78K | +9,568 | 0.00% |
| BlackRock, Inc. | 27,910 | 0.87% | $136.20K | −685 | 0.00% |
| Acadian Asset Management LLC | 22,496 | 0.70% | $109.00K | −1,700 | 0.00% |
| Vanguard Fiduciary Trust Co | 17,049 | 0.53% | $83.20K | – | 0.00% |
| Deltec Asset Management LLC | 15,000 | 0.47% | $73.20K | New | 0.01% |
| UBS Group AG | 13,565 | 0.42% | $66.20K | −13,936 | 0.00% |
| Hrt Financial LP | 12,712 | 0.40% | $62.00K | New | 0.00% |
| Fiduciary Trust Co | 10,750 | 0.33% | $52.46K | – | 0.00% |
| Gts Securities LLC | 10,000 | 0.31% | $48.80K | New | 0.00% |
| Morgan Stanley | 2,389 | 0.07% | $11.66K | −261 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 30 | 4M | 100.0% | 5 / 5 | 7 / 9 | 3M | 1M |
| Q1 2026 | 35 | 2M | 55.3% | 12 / 6 | 4 / 6 | 0M | 0M |
| Q4 2025 | 30 | 2M | 49.0% | 6 / 5 | 7 / 7 | 0M | 0M |
| Q3 2025 | 32 | 2M | 51.2% | 6 / 15 | 6 / 15 | 0M | 0M |
| Q2 2025 | 41 | 2M | 54.5% | 5 / 9 | 10 / 6 | 0M | 0M |
| Q1 2025 | 42 | 2M | 56.4% | 2 / 11 | 11 / 6 | 0M | 0M |
| Q4 2024 | 46 | 2M | 58.5% | 10 / 10 | 10 / 9 | 0M | 0M |
| Q3 2024 | 45 | 2M | 60.1% | 10 / 8 | 7 / 9 | 0M | 0M |
| Q2 2024 | 45 | 2M | 62.6% | 3 / 8 | 11 / 9 | 0M | 0M |
| Q1 2024 | 51 | 2M | 62.7% | 7 / 13 | 14 / 8 | 1M | 0M |
| Q4 2023 | 52 | 2M | 50.9% | 8 / 15 | 10 / 7 | 0M | 0M |
| Q3 2023 | 51 | 2M | 50.3% | 2 / 14 | 13 / 6 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
13 funds held PASG in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PASG | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 78,764 | 2.45% | $384.37K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 35,200 | 1.09% | $171.78K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 18,535 | 0.58% | $106.95K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 6,427 | 0.20% | $37.08K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 4,783 | 0.15% | $27.60K | 0.00% | May 31, 2026 |
| LVIP Dimensional U.S. Core Equity 2 Fund | 2,022 | 0.06% | $9.87K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 1,897 | 0.06% | $10.95K | 0.00% | May 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 792 | 0.02% | $3.54K | 0.00% | Jul 31, 2026 |
| Diversified Equity Alpha Master Portfolio | 504 | 0.02% | $2.46K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| William Chou | PRESIDENT AND CEO, Director | 6,524 | 0.20% | Mar 18, 2026 |
| Kathleen Borthwick | CFO | 5,402 | 0.17% | Mar 18, 2026 |
| Edgar B. Cale | GC & CORPORATE SECRETARY | 45,995 | 1.43% | Mar 18, 2025 |
| Athena Countouriotis | Director | 18,900 | 0.59% | May 21, 2026 |
| Derrell Porter | Director | – | – | May 21, 2026 |
| Thomas Richard Kassberg | Director | – | – | May 21, 2026 |
| Maxine Gowen | Director | – | – | May 21, 2026 |
| Sandip Kapadia | Director | 0 | – | May 21, 2026 |
| Dolan Sondhi | Director | – | – | May 21, 2026 |
| Saqib Islam | Director | 5,000 | 0.16% | May 30, 2025 |
| Weston Nichols | 10% owner | 673,759 | 20.94% | Jun 29, 2026 |
| Capital Management LP Lynx1 | 10% owner | 591,696 | 18.39% | Jun 29, 2026 |
| Capital GP VII LLC OrbiMed | 10% owner | 6,885,572 | 213.98% | Jun 26, 2025 |
| Advisors Llc Orbimed | 10% owner | 6,066,343 | 188.52% | Jun 26, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Weston Nichols 10% owner | Jun 25, 2026 | Buy | +50,055 | $4.12 | $206.23K | 673,759 |
| William Chou PRESIDENT AND CEO, Director | Jan 8, 2026 | Sale | −4,076 | $18.44 | $75.16K | 6,524 |
| William Chou PRESIDENT AND CEO, Director | Jan 8, 2026 | Option exercise | +10,000 | – | – | 10,600 |
| Kathleen Borthwick CFO | Jan 8, 2026 | Sale | −2,062 | $18.44 | $38.02K | 5,402 |
| Kathleen Borthwick CFO | Jan 8, 2026 | Option exercise | +5,000 | – | – | 7,464 |
| Weston Nichols 10% owner | Sep 15, 2025 | Buy | +11,900 | $6.99 | $83.18K | 623,704 |
| Weston Nichols 10% owner | Sep 12, 2025 | Buy | +19,783 | $6.99 | $138.28K | 611,804 |
| Weston Nichols 10% owner | Sep 11, 2025 | Buy | +325 | $6.96 | $2.26K | 592,021 |
| Capital Management LP Lynx1 10% owner | Jul 24, 2025 | Buy | +66,423 | $5.71 | $379.28K | 591,696 |
| Capital Management LP Lynx1 10% owner | Jul 23, 2025 | Buy | +49,302 | $5.74 | $282.99K | 525,273 |
| Capital Management LP Lynx1 10% owner | Jul 22, 2025 | Buy | +13,123 | $5.44 | $71.39K | 475,971 |
| Advisors Llc Orbimed 10% owner | Jun 26, 2025 | Sale | −213,257 | $0.33 | $70.37K | 6,066,343 |
| Advisors Llc Orbimed 10% owner | Jun 25, 2025 | Sale | −138,800 | $0.33 | $45.80K | 6,279,600 |
| Advisors Llc Orbimed 10% owner | Jun 24, 2025 | Sale | −231,600 | $0.35 | $81.06K | 6,418,400 |
| Advisors Llc Orbimed 10% owner | Apr 24, 2025 | Sale | −68,195 | $0.32 | $21.82K | 6,650,000 |
| Advisors Llc Orbimed 10% owner | Apr 23, 2025 | Sale | −89,328 | $0.34 | $30.37K | 6,718,195 |
| Advisors Llc Orbimed 10% owner | Apr 22, 2025 | Sale | −78,049 | $0.34 | $26.54K | 6,807,523 |
| Capital GP VII LLC OrbiMed 10% owner | Apr 17, 2025 | Sale | −77,090 | $0.33 | $25.44K | 6,885,572 |
| Capital GP VII LLC OrbiMed 10% owner | Apr 16, 2025 | Sale | −61,638 | $0.33 | $20.34K | 6,962,662 |
| Capital GP VII LLC OrbiMed 10% owner | Apr 15, 2025 | Sale | −10,326 | $0.38 | $3.92K | 7,024,300 |
| Kathleen Borthwick CFO | Feb 11, 2025 | Sale | −3,183 | $0.53 | $1.69K | 41,283 |
| Kathleen Borthwick CFO | Feb 10, 2025 | Option exercise | +8,000 | – | – | 44,466 |
| Advisors Llc Orbimed 10% owner | Jan 14, 2025 | Sale | −79,024 | $0.60 | $47.41K | 7,034,626 |
| Advisors Llc Orbimed 10% owner | Jan 13, 2025 | Sale | −17,986 | $0.64 | $11.51K | 7,113,650 |
| Advisors Llc Orbimed 10% owner | Jan 10, 2025 | Sale | −126,209 | $0.66 | $83.30K | 7,131,636 |
| Capital GP VII LLC OrbiMed 10% owner | Jan 8, 2025 | Sale | −75,007 | $0.68 | $51.00K | 7,257,845 |
| Capital GP VII LLC OrbiMed 10% owner | Jan 7, 2025 | Sale | −52,536 | $0.71 | $37.30K | 7,332,852 |
| Capital GP VII LLC OrbiMed 10% owner | Jan 6, 2025 | Sale | −19,481 | $0.77 | $15.00K | 7,385,388 |
| Capital Management LP Lynx1 10% owner | Dec 27, 2024 | Buy | +373,645 | $0.65 | $242.87K | 9,256,953 |
| Capital GP VII LLC OrbiMed 10% owner | Dec 20, 2024 | Sale | −230,321 | $0.60 | $138.19K | 7,404,869 |
| Advisors Llc Orbimed 10% owner | Dec 11, 2024 | Sale | −80 | $0.80 | $64 | 7,635,190 |
| Advisors Llc Orbimed 10% owner | Dec 10, 2024 | Sale | −8,015 | $0.80 | $6.41K | 7,635,270 |
| Advisors Llc Orbimed 10% owner | Dec 9, 2024 | Sale | −54,181 | $0.84 | $45.51K | 7,643,285 |
| Capital GP VII LLC OrbiMed 10% owner | Dec 6, 2024 | Sale | −20,903 | $0.82 | $17.14K | 7,697,466 |
| Capital GP VII LLC OrbiMed 10% owner | Dec 4, 2024 | Sale | −76,200 | $0.79 | $60.20K | 7,718,369 |
| Capital Management LP Lynx1 10% owner | Nov 27, 2024 | Buy | +29,300 | $0.67 | $19.63K | 8,883,308 |
| Capital Management LP Lynx1 10% owner | Nov 26, 2024 | Buy | +167,055 | $0.71 | $118.61K | 8,854,008 |
| Capital Management LP Lynx1 10% owner | Nov 25, 2024 | Buy | +259,998 | $0.56 | $145.60K | 8,686,953 |
| Advisors Llc Orbimed 10% owner | Sep 19, 2024 | Sale | −39,300 | $0.71 | $27.90K | 7,794,569 |
| Capital GP VII LLC OrbiMed 10% owner | Sep 18, 2024 | Sale | −25,631 | $0.73 | $18.71K | 7,833,869 |
| Capital GP VII LLC OrbiMed 10% owner | Sep 17, 2024 | Sale | −111,400 | $0.73 | $81.32K | 7,859,500 |
| Capital GP VII LLC OrbiMed 10% owner | Sep 16, 2024 | Sale | −63,100 | $0.74 | $46.69K | 7,970,900 |
| Kathleen Borthwick SVP, INTERIM CFO | Feb 13, 2024 | Sale | −1,470 | $0.97 | $1.43K | 28,466 |
| Mark S. Forman CHIEF MEDICAL OFFICER | Feb 13, 2024 | Sale | −1,638 | $0.97 | $1.59K | 48,631 |
| Kathleen Borthwick SVP, INTERIM CFO | Feb 10, 2024 | Option exercise | +4,000 | – | – | 29,936 |
| Mark S. Forman CHIEF MEDICAL OFFICER | Feb 10, 2024 | Option exercise | +5,000 | – | – | 50,269 |
| Kathleen Borthwick SVP, Interim CFO | Jan 2, 2024 | Sale | −10,672 | $0.91 | $9.71K | 25,936 |
| Mark S. Forman Chief Medical Officer | Jan 2, 2024 | Sale | −15,813 | $0.91 | $14.39K | 45,269 |
| Edgar B. Cale GC & Corporate Secretary | Jan 2, 2024 | Sale | −15,813 | $0.91 | $14.39K | 45,995 |
| Kathleen Borthwick SVP, Interim CFO | Dec 31, 2023 | Option exercise | +30,000 | – | – | 36,608 |
| Mark S. Forman Chief Medical Officer | Dec 31, 2023 | Option exercise | +50,000 | – | – | 61,082 |
| Edgar B. Cale GC & Corporate Secretary | Dec 31, 2023 | Option exercise | +50,000 | – | – | 61,808 |
| Simona King Chief Financial Officer | Jul 28, 2023 | Sale | −11,453 | $0.88 | $10.08K | 23,994 |
| Simona King Chief Financial Officer | Jul 28, 2023 | Option exercise | +31,250 | – | – | 35,447 |
| Advisors Llc Orbimed 10% owner | Jun 28, 2023 | Buy | +575,195 | $0.84 | $483.16K | 8,034,000 |
| Advisors Llc Orbimed 10% owner | Jun 27, 2023 | Buy | +617,382 | $0.84 | $518.60K | 7,458,805 |
| Alexandros Fotopoulos Chief Technical Officer | Jun 16, 2023 | Sale | −4,052 | $0.93 | $3.77K | 28,693 |
| Alexandros Fotopoulos Chief Technical Officer | Jun 15, 2023 | Option exercise | +12,500 | – | – | 32,745 |
| Simona King Chief Financial Officer | Apr 18, 2023 | Sale | −2,053 | $1.05 | $2.16K | 2,053 |
| Simona King Chief Financial Officer | Apr 18, 2023 | Option exercise | +6,250 | – | – | 6,250 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Passage BIO's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| William Chou Officer | Jan 9, 2026 | 4,076 | $75.12K | Jan 9, 2026 | Restricted Stock |
| OrbiMed Private Investments VII, LP Stockholder | Jul 21, 2025 | 132,645 | $737.51K | Jul 21, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Jul 15, 2025 | 53,293 | $361.86K | Jul 15, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Jul 7, 2025 | 259,000 | $112.15K | Jul 7, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Jun 24, 2025 | 1,076,120 | $378.36K | Jun 24, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Apr 15, 2025 | 787,179 | $301.49K | Apr 15, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Jan 6, 2025 | 1,140,740 | $945.67K | Jan 6, 2025 | IPO |
| OrbiMed Private Investments VII, LP Stockholder | Dec 4, 2024 | 2,985,518 | $2.66M | Dec 4, 2024 | IPO |
| Worldwide Healthcare Trust PLC Stockholder | Dec 4, 2024 | 2,028,307 | $1.81M | Dec 4, 2024 | IPO |
| OrbiMed Private Investments VII, LP Owner | Sep 16, 2024 | 927,572 | $748.55K | Sep 16, 2024 | IPO |
| Worldwide Healthcare Trust PLC Owner | Sep 16, 2024 | 241,328 | $194.75K | Sep 16, 2024 | IPO |
See a number that looks wrong?